Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB

International Journal of Oncology

Volumn 38, Issue 1, 2011, Pages 241-247

  Levati, Lauretta ^a   Ruffini, Federica ^a   Muzi, Alessia ^b   Umezawa, Kazuo ^c   Graziani, Grazia ^b   D'Atri, Stefania ^a   Lacal, Pedro Miguel ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Melanoma; NF B; PlGF; Temozolomide resistance

Indexed keywords

6 O BENZYLGUANINE; 6 O METHYLGUANINE; DNA METHYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PLACENTAL GROWTH FACTOR; TEMOZOLOMIDE; VASCULOTROPIN A;

ARTICLE; CELL PROTECTION; CYTOTOXICITY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MELANOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

DACARBAZINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; NF-KAPPA B; PREGNANCY PROTEINS; RNA, ANTISENSE; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 78650841055     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000844     Document Type: Article

References (37)

1. Ho MC, Chen CN, Lee H, Hsieh FJ, Shun CT, Chang CL, et al: Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 250: 237-249, 2007.
2. Fischer C, Mazzone M, Jonckx B and Carmeliet P: FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8: 942-956, 2008.
3. Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B and Wu Y: Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (human antibody targeting vascular endothelial growth factor receptor-1). Cancer 116: 1027-1032, 2010.
4. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, et al: Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt-1 and Flk-1. Nat Med 9: 936-943, 2003.
5. Adini A, Kornaga T, Firoozbakht F and Benjamin LE: Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 62: 2749-2752, 2002.
6. Zhou Y, Bellingard V, Feng K-T, McMaster M and Fisher SJ: Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PlGF, and VEGF-C. Dev Biol 263: 114-125, 2003. (Pubitemid 37268007)
7. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, et al: The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 119: 1519-1529, 2006. (Pubitemid 44258756)
8. Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, et al: Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 12: 6573-6584, 2006.
9. Fragoso R, Pereira T, Wu Y, Zhu Z, Cabecadas J and Dias S: VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 107: 1608-1616, 2006.
10. Lacal P, Failla CM, Pagani E, Odorisio T, Schietroma C, Cianfarani, F, Falcinelli S, et al: Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115: 1000-1007, 2000.
11. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, et al: Overproduction of VEGF165 concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signalling. J Invest Dermatol 123: 1151-1161, 2004. (Pubitemid 39586840)
12. Graeven U, Fiedler W and Karpinski S: Melanoma-associated expression of vascular endothelial growth factor and its receptors Flt-1 and KDR. J Cancer Res Clin Oncol 125: 621-629, 1999.
13. Lacal PM, Ruffini F, Pagani E and D'Atri S: An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 27: 1625-1632, 2005.
14. Marcellini M, De Luca N, Riccioni T, Ciucci A, Orecchia A, Lacal PM, et al: Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol 169: 643-654, 2006.
15. Li Y and McClay EF: Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 29: 413-426, 2002.
16. Tawbi HA and Kirkwood JM: Management of metastatic melanoma. Semin Oncol 34: 532-545, 2007.
17. Bael TE, Peterson BL and Gollob JA: Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Mol Res 18: 147-151, 2008.
18. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT and Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 35-61, 1997.
19. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36: 457-462, 1987.
20. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV and Kovacs K: Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res 29: 3759-3768, 2009.
21. Casorelli I, Russo MT and Bignami M: Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med Chem 8: 368-380, 2008. (Pubitemid 351761422)
22. Greten FR and Karin M: The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 206: 193-199, 2004.
23. Sun C, Chan F, Briassouli P and Linardopoulos S: Aurora kinase inhibition downregulates NF-kappaB and sensitises tumour cells to chemotherapeutic agents. Biochem Biophys Res Commun 352: 220-225, 2007.
24. Mohamed MR and McFadden G: NFκB inhibitors: strategies from poxviruses. Cell Cycle 8: 3125-3132, 2009.
25. Kucharczak J, Simmons MJFY and Gelinas C: To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22: 8961-8982, 2003.
26. Luo JL, Kamata H and Karin M: IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115: 2625-2632, 2005. (Pubitemid 41434385)
27. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
28. 6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 152: 49-61, 2000.
29. Tentori L, Forini O, Fossile E, Muzi A, Vergati M, Portarena I, et al: N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity. Mol Pharmacol 67: 572-581, 2005.
30. Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, et al: DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int J Oncol 29: 713-719, 2006.
31. Horie R, Watanabe M, Okamura T, Taira M, Shoda M, Motoji T, et al: DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 20: 800-806, 2006.
32. 6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 304: 661-668, 2003.
33. Tentori L and Graziani G: Recent approaches to improve the antitumor efficacy of temozolomide. Curr Med Chem 16: 245-257, 2009.
34. Uffort DG, Grimm EA and Ellerhorst JA: NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol 129: 148-154, 2008.
35. Yamamoto M, Horie R, Takeiri M, Kozawa I and Umezawa K: Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 51: 5780-5788, 2008.
36. Ariga A, Namekawa J, Matsumoto N, Inoue J and Umezawa K: Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 277: 24625-24630, 2002.
37. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al: Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475, 2007.